Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Marinus Pharmaceuticals Inc is a biotechnology business based in the US. Marinus Pharmaceuticals shares (MRNS) are listed on the NASDAQ and all prices are listed in US Dollars. Marinus Pharmaceuticals employs 113 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $4.84 |
|---|---|
| 52-week range | $3.97 - $19.40 |
| 50-day moving average | $5.75 |
| 200-day moving average | $9.55 |
| Wall St. target price | $30.11 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.48 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.84 from 2022-06-30
| 1 week (2022-06-24) | -3.01% |
|---|---|
| 1 month (2022-05-28) | N/A |
| 3 months (2022-04-01) | -48.46% |
| 6 months (2021-12-31) | -59.26% |
| 1 year (2021-07-01) | -74.12% |
|---|---|
| 2 years (2020-07-01) | 81.27% |
| 3 years (2019-07-01) | 12.82% |
| 5 years (2017-06-30) | 253.28% |
| Revenue TTM | $27.7 million |
|---|---|
| Gross profit TTM | $-54,568,000 |
| Return on assets TTM | -38.4% |
| Return on equity TTM | -116.86% |
| Profit margin | 0% |
| Book value | $0.97 |
| Market capitalisation | $189.1 million |
TTM: trailing 12 months
We're not expecting Marinus Pharmaceuticals to pay a dividend over the next 12 months.
Marinus Pharmaceuticals's shares were split on a 1:4 basis on 23 September 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marinus Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Marinus Pharmaceuticals shares which in turn could have impacted Marinus Pharmaceuticals's share price.
Over the last 12 months, Marinus Pharmaceuticals's shares have ranged in value from as little as $3.97 up to $19.397. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marinus Pharmaceuticals's is 1.5027. This would suggest that Marinus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Marinus Pharmaceuticals, Inc. , a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.